Drug Trial Radar · NCT02494895
Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)
Last checked: Nov 19, 2026Latest source record: Jun 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,056
Planned (sponsor's estimate)
Start
Aug 1, 2015
Primary completion
May 2023
Study completion May 2023
Sponsor
- Lead sponsor
- Yonsei UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 19 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the clinical outcomes of dual antiplatelet therapy with aspirin and ticagrelor vs. ticagrelor monotherapy at 3 months after PCI in patients with acute coronary syndrome.
Conditions
- Acute Coronary Syndrome
Interventions
Ticagrelor monotherapyDrug
Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)Drug
Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major adverse cardiovascular clinical events (MACCE)Time frame: 1 year after the procedure
- major bleedingTime frame: 1 year after the procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.